SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-000953
Filing Date
2021-08-05
Accepted
2021-08-05 16:36:30
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mirm-20210805.htm   iXBRL 8-K 49710
2 EX-99.1 mirm-20210805ex99_1.htm EX-99.1 207202
3 GRAPHIC img101024312_0.jpg GRAPHIC 7945
  Complete submission text file 0000950170-21-000953.txt   402011

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mirm-20210805_lab.xml EX-101.LAB 14046
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mirm-20210805.xsd EX-101.SCH 2438
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mirm-20210805_pre.xml EX-101.PRE 10378
7 EXTRACTED XBRL INSTANCE DOCUMENT mirm-20210805_htm.xml XML 4895
Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404
Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Filer) CIK: 0001759425 (see all company filings)

IRS No.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38981 | Film No.: 211148957
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences